Drug Design -- United States -- Congresses : Envisioning a transformed clinical trials enterprise in the United States : establishing an agenda for 2020 : workshop summary / Neil Weisfeld, Rebecca A. English, and Anne B. Claiborne, Rapporteurs ; Forum on Drug Discovery, Development, and Translation ; Board on Health Sciences Policy, Institute of Medicine of the National Academies
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis
